ATE360442T1 - Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen - Google Patents
Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständenInfo
- Publication number
- ATE360442T1 ATE360442T1 AT03702642T AT03702642T ATE360442T1 AT E360442 T1 ATE360442 T1 AT E360442T1 AT 03702642 T AT03702642 T AT 03702642T AT 03702642 T AT03702642 T AT 03702642T AT E360442 T1 ATE360442 T1 AT E360442T1
- Authority
- AT
- Austria
- Prior art keywords
- combination
- treating hyperproliferative
- compositions
- methods
- relates
- Prior art date
Links
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 2
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35691202P | 2002-02-14 | 2002-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE360442T1 true ATE360442T1 (de) | 2007-05-15 |
Family
ID=27734705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03702642T ATE360442T1 (de) | 2002-02-14 | 2003-02-14 | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1476192B1 (de) |
| JP (1) | JP5053503B2 (de) |
| CN (1) | CN100591355C (de) |
| AT (1) | ATE360442T1 (de) |
| AU (1) | AU2003205768A1 (de) |
| BR (1) | BR0307629A (de) |
| CA (1) | CA2476000A1 (de) |
| DE (1) | DE60313434T2 (de) |
| ES (1) | ES2283744T3 (de) |
| PT (1) | PT1476192E (de) |
| WO (1) | WO2003068265A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| ATE514434T1 (de) * | 2004-02-25 | 2011-07-15 | Dana Farber Cancer Inst Inc | Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum |
| AU2005230818B2 (en) | 2004-04-02 | 2010-11-25 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| US7329495B2 (en) | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
| AR053090A1 (es) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
| WO2007035744A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| EP2400985A2 (de) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors |
| US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519281A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2542893A2 (de) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren |
| AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| JP2013522215A (ja) | 2010-03-09 | 2013-06-13 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 組合わせ抗癌療法 |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| CA2941010A1 (en) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
| US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ226799A (en) * | 1987-11-06 | 1991-08-27 | Oncogen | Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor |
| DE4129533A1 (de) * | 1991-09-05 | 1993-03-11 | Max Planck Gesellschaft | Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| CN1117097C (zh) * | 1998-05-29 | 2003-08-06 | 北京金赛狮生物制药技术开发有限责任公司 | 类胰岛素生长因子受体基因的反义核酸的抑癌作用 |
-
2003
- 2003-02-14 CA CA002476000A patent/CA2476000A1/en not_active Abandoned
- 2003-02-14 ES ES03702642T patent/ES2283744T3/es not_active Expired - Lifetime
- 2003-02-14 DE DE60313434T patent/DE60313434T2/de not_active Expired - Lifetime
- 2003-02-14 AT AT03702642T patent/ATE360442T1/de active
- 2003-02-14 AU AU2003205768A patent/AU2003205768A1/en not_active Abandoned
- 2003-02-14 PT PT03702642T patent/PT1476192E/pt unknown
- 2003-02-14 WO PCT/EP2003/001507 patent/WO2003068265A1/en not_active Ceased
- 2003-02-14 CN CN03803734A patent/CN100591355C/zh not_active Expired - Fee Related
- 2003-02-14 JP JP2003567445A patent/JP5053503B2/ja not_active Expired - Fee Related
- 2003-02-14 EP EP03702642A patent/EP1476192B1/de not_active Expired - Lifetime
- 2003-02-14 BR BR0307629-6A patent/BR0307629A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1476192B1 (de) | 2007-04-25 |
| CA2476000A1 (en) | 2003-08-21 |
| PT1476192E (pt) | 2007-07-26 |
| EP1476192A1 (de) | 2004-11-17 |
| WO2003068265A1 (en) | 2003-08-21 |
| ES2283744T3 (es) | 2007-11-01 |
| CN100591355C (zh) | 2010-02-24 |
| JP5053503B2 (ja) | 2012-10-17 |
| CN1630534A (zh) | 2005-06-22 |
| JP2005517040A (ja) | 2005-06-09 |
| DE60313434T2 (de) | 2008-01-10 |
| DE60313434D1 (de) | 2007-06-06 |
| BR0307629A (pt) | 2005-01-11 |
| AU2003205768A1 (en) | 2003-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE360442T1 (de) | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen | |
| ATE489955T1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
| DE60227095D1 (de) | Zusammensetzungen und verfahren zur behandlung von abgebundenem gips | |
| EP1701664A4 (de) | System und verfahren zur behandlung von gewebe | |
| EP1626730A4 (de) | Verfahren, gerät und zusammensetzung zur behandlung von akne | |
| NO20052888L (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
| MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
| DE50312145D1 (de) | Vorrichtung zur behandlung von frakturen des femur | |
| TW200514776A (en) | Aminotriazole compounds useful as inhibitors of protein kinases | |
| EP1572075A4 (de) | Verfahren zur behandlung von krankheiten in verbindung mit abnormaler kinasewirkung | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| DE602004017736D1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| DE60118889D1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
| ATE448775T1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
| DE60034871D1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
| TW200630090A (en) | Triazoles useful as inhibitors of protein kinases | |
| DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
| ATE415163T1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| EP1499190A4 (de) | Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
| DE60327856D1 (de) | Zusammensetzungen und verfahren zur hautbräunung | |
| EA200700403A1 (ru) | ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1476192 Country of ref document: EP |